# US 2019/0167718 A1 · Compositions and methods for activating antigen presenting cells with chimeric poliovirus > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0167718 A1 - Document ID: US20190167718A1 - Status: Published application - Kind: A1 - Application number: 16/321,144 - Filed: 2017-06-29 - Published: 2019-06-06 - Earliest claimed: 2016-06-29 - Assignees: Duke University - Applicants: Duke University - Inventors: Smita Nair; Michael Brown; Darell Bigner; Matthias Gromeier - Web page: https://patentgrep.com/patent/US20190167718A1 ## CPC - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 9/0043: {Nose} - A61K 9/007: {Pulmonary tract; Aromatherapy} - A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links - A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) - A61K 35/76: Viruses; Subviral particles; Bacteriophages - A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/17: Monocytes; Macrophages - A61K 40/19: Dendritic cells - A61K 40/24: Antigen-presenting cells [APC] - A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor} - A61K 40/46: Viral antigens - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 35/00: Antineoplastic agents - C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis} - A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants} - A61K 2039/55588: {Adjuvants of undefined constitution} - C12N 2770/32611: Poliovirus - C12N 2770/32632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Chimeric poliovirus is capable of activating antigen presenting cells. The activation of the antigen presenting cells may be in vitro, ex vivo, or in vivo. The activated antigen presenting cells may be administered alone or with an antigen or vaccine. The activated antigen may be loaded in vitro or ex vivo with antigen to form antigen-loaded, activated, antigen presenting cells. These may be administered therapeutically. Therapeutic administration of antigen presenting cells may be used as an adjuvant to other therapies. ## Claims ### Claim 1 A method for activating an antigen presenting cell, comprising: contacting an antigen presenting cell with chimeric poliovirus or RNA encoding the chimeric poliovirus in an amount effective to activate an antigen presenting cell, wherein the contacting is performed ex vivo, or dermally. ### Claim 2 (depends on 1) The method according to claim 1 wherein the antigen presenting cell is a dendritic cell. ### Claim 3 (depends on 1) The method according to claim 1, wherein the antigen presenting cell is contacted with virus particles of the chimeric poliovirus. ### Claim 4 (depends on 1) The method according to claim 1 wherein the antigen presenting cell is contacted with RNA encoding the chimeric poliovirus. ### Claim 5 (depends on 4) The method according to claim 4 wherein the RNA is mRNA. ### Claim 6 (depends on 1) The method according to claim 1 further comprising contacting the antigen presenting cell with an antigen. ### Claim 7 A method for activating an antigen presenting cell, comprising: contacting in vitro an isolated antigen presenting cell with chimeric poliovirus or RNA encoding the chimeric poliovirus in an amount effective to activate the antigen presenting cell. ### Claim 8 (depends on 7) The method according to claim 7 wherein the antigen presenting cell is a dendritic cell. ### Claim 9 (depends on 7) The method according to claim 7 wherein the antigen presenting cell is contacted with virus particles of the chimeric poliovirus. ### Claim 10 (depends on 7) The method according to claim 7 wherein the antigen presenting cell is contacted with RNA encoding the chimeric poliovirus. ### Claim 11 (depends on 10) The method according to claim 10 wherein the RNA is mRNA. ### Claim 12 (depends on 7) The method according to claim 7 further comprising contacting the antigen presenting cell with an antigen. ### Claim 13 (depends on 12) The method according to claim 12 wherein the antigen presenting cell is contacted with antigen prior to contact with chimeric poliovirus. ### Claim 14 (depends on 12) The method according to claim 12 wherein the antigen presenting cell is contacted with chimeric poliovirus prior to contact with antigen. ### Claim 15 (depends on 12) The method according to claim 12 wherein the antigen presenting cell is contacted with concurrently with chimeric poliovirus and antigen. ### Claim 16 A method of performing immunotherapy, comprising: administering an activated antigen presenting cell that has been loaded with an antigen to an individual, wherein the activated antigen presenting cell is prepared by contacting an antigen presenting cell with chimeric poliovirus or RNA encoding the chimeric poliovirus in an amount effective to activate the antigen presenting cell. ### Claim 17 (depends on 16) The method according to claim 16 wherein the antigen presenting cell is contacted with virus particles of the chimeric poliovirus. ### Claim 18 (depends on 16) The method according to claim 16 wherein the antigen presenting cell is contacted with RNA encoding the chimeric poliovirus. ### Claim 19 (depends on 18) The method according to claim 18 wherein the RNA is mRNA. ### Claim 20 (depends on 16) The method according to claim 16 wherein the antigen is from a pathogen, wherein the pathogen is selected from the group consisting of bacteria, a virus, and a parasite. ### Claim 21 (depends on 16) The method according to claim 16 wherein the antigen is a tumor antigen. ### Claim 22 (depends on 16) The method according to claim 16 wherein the antigen is loaded by introduction of mRNA to the antigen presenting cell. ### Claim 23 (depends on 16) The method according to claim 16 wherein the antigen is loaded by contacting the antigen presenting cell with the antigen, wherein the antigen is a protein. ### Claim 24 (depends on 23) The method according to claim 23 wherein the antigen is bound to antibody having binding specificity for the antigen. ### Claim 25 (depends on 23) The method according to claim 23 wherein a cell lysate containing antigen is used for loading the dendritic cell. ### Claim 26 A method of treating a disease comprising: administering to an individual an activated antigen presenting cell prepared by contacting an antigen presenting cell with (a) chimeric poliovirus or RNA encoding the chimeric poliovirus in an amount effective to activate the antigen presenting cell; and (b) an antigen. ### Claim 27 (depends on 26) The method according to claim 26 wherein the dendritic cell is contacted with virus particles of the chimeric poliovirus. ### Claim 28 (depends on 26) The method according to claim 26 wherein the antigen presenting cell is contacted with RNA encoding the chimeric poliovirus. ### Claim 29 (depends on 28) The method according to claim 28 wherein the RNA is mRNA. ### Claim 30 (depends on 26) The method according to claim 26 wherein the antigen is from a pathogen, wherein the pathogen is selected from the group consisting of bacteria, a virus, and a parasite. ### Claim 31 (depends on 26) The method according to claim 26 wherein the antigen is a tumor antigen. ### Claim 32 (depends on 26) The method according to claim 26 wherein the antigen comprises a nucleic acid molecule. ### Claim 33 (depends on 32) The method according to claim 32 wherein the nucleic acid molecule comprises mRNA. ### Claim 34 (depends on 26) The method according to claim 26 wherein the antigen comprises a protein. ### Claim 35 (depends on 34) The method according to claim 34 wherein the protein is bound to an antibody having binding specificity for the antigen. ### Claim 36 (depends on 26) The method according to claim 26 wherein antigen is contained in a cell lysate. ### Claim 37 (depends on 26) The method according to claim 26 wherein the disease comprises an infectious disease. ### Claim 38 (depends on 26) The method according to claim 26 wherein the disease is cancer. ### Claim 39 An immunogenic composition comprising: an antigen selected from the group consisting of: an antigen of a bacterial pathogen, an antigen of a pathogenic parasite, an antigen of a non-polio virus, and a tumor antigen; and an adjuvant comprising a chimeric poliovirus or RNA encoding the chimeric poliovirus. ### Claim 40 (depends on 39) The immunogenic composition according to claim 39 wherein the adjuvant comprises virus particles of the chimeric poliovirus. ### Claim 41 (depends on 39) The immunogenic composition according to claim 39 wherein the adjuvant comprises RNA encoding the chimeric poliovirus. ### Claim 42 (depends on 41) The immunogenic composition according to claim 41 wherein the RNA is mRNA. ### Claim 43 (depends on 39) The immunogenic composition according to claim 39 wherein the antigen is from a pathogen, wherein the pathogen is selected from the group consisting of bacteria, a non-polio virus, and a parasite. ### Claim 44 (depends on 39) The immunogenic composition according to claim 39 wherein the antigen is a tumor antigen. ### Claim 45 (depends on 39) The immunogenic composition according to claim 39 wherein the antigen comprises a nucleic acid molecule. ### Claim 46 (depends on 39) The immunogenic composition according to claim 39 wherein the nucleic acid molecule comprise mRNA. ### Claim 47 (depends on 39) The immunogenic composition according to claim 39 wherein the antigen comprises a protein. ### Claim 48 (depends on 47) The immunogenic composition according to claim 47 wherein the protein is bound to an antibody having binding specificity for the antigen. ### Claim 49 (depends on 39) The immunogenic composition according to claim 39 wherein antigen is contained in a cell lysate. ### Claim 50 (depends on 39) The immunogenic composition according to claim 39 further comprising a pharmaceutically acceptable carrier. ### Claim 51 (depends on 50) The immunogenic composition according to claim 50 for use in a vaccine. ### Claim 52 (depends on 39) A method of eliciting an immune response comprising administering to an individual the immunogenic composition according to claim 39. ### Claim 53 (depends on 52) The method according to claim 52 wherein the immunogenic composition is administered with a pharmaceutically acceptable carrier. ### Claim 54 (depends on 53) The method according to claim 53 wherein the immunogenic composition is administered dermally. ### Claim 55 (depends on 7) The method of claim 7 further comprising: administering the antigen presenting cell to a human subject. ### Claim 56 (depends on 1) The method of claim 1 wherein the contacting is performed ex vivo and the method further comprises the step of administering the antigen presenting cell to a human subject. ### Claim 57 A method for activating an antigen presenting cell, comprising: delivering a chimeric poliovirus or RNA encoding the chimeric poliovirus directly to mucosa or skin of a human in an amount effective to activate antigen presenting cells in the mucosa or skin. ### Claim 58 (depends on 57) The method of claim 57 wherein delivery is to the mucosa and the mucosa is in lung of the human. ### Claim 59 (depends on 57) The method of claim 57 wherein delivery is to the mucosa and the mucosa is in stomach of the human. ### Claim 60 (depends on 57) The method of claim 57 wherein delivery is to the mucosa and the mucosa is in nose of the human. ### Claim 61 (depends on 57) The method of claim 57 wherein delivery is to the mucosa and the mucosa is in intestines of the human. ### Claim 62 (depends on 57) The method of claim 57 wherein delivery is to the mucosa and the mucosa is cytologically normal mucosa. ### Claim 63 (depends on 57) The method of claim 57 wherein delivery is to the skin and the skin is cytologically normal skin. ### Claim 64 (depends on 57) The method of claim 57 wherein the human has multifocal or metastatic lesions.